TNXP Overview

Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company focused on developing and commercializing therapeutics to treat and vaccines to prevent, disease and alleviate suffering. Its development portfolio is focused on central nervous system (CNS) disorders. Its product candidates include TNX-102 SL, TNX-1300, TNX-2900, TNX-1900, TNX-1500, TNX-801, TNX-1800, TNX-4200, and TNX-1700. TNX-102 SL is for the management of fibromyalgia. Its CNS portfolio includes TNX-1300 (cocaine esterase), a biologic designed to treat cocaine intoxication that has a therapy designation. Its immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. It markets Zembrace SymTouch (sumatriptan injection) 3 mg and Tosymra (sumatriptan nasal spray) 10 mg.

Wall Street analysts forecast TNXP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TNXP is67.50 USD with a low forecast of 65.00 USD and a high forecast of 70.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Tonix Pharmaceuticals Holding Corp revenue for the last quarter amounts to 5.39M USD, increased 108.75

Tonix Pharmaceuticals Holding Corp. EPS for the last quarter amounts to -3.96 USD, decreased -59.67

Tonix Pharmaceuticals Holding Corp (TNXP) has 142 emplpoyees as of May 11 2026.

Today TNXP has the market capitalization of 200.15M USD.